Patient Derived Xenograft/PDX Models Market

Table of Contents

1 Introduction (Page No. - 12)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 16)
    2.1 Research Methodology Steps
    2.2 Secondary and Primary Research Methodology
           2.2.1 Secondary Research
                    2.2.1.1 Key Data From Secondary Sources
           2.2.2 Primary Research
                    2.2.2.1 Key Industry Insights
                    2.2.2.2 Key Data From Primary Sources
                    2.2.2.3 Key Insights From Primary Sources
    2.3 Market Size Estimation Methodology
    2.4 Market Forecast Methodology
    2.5 Market Data Validation and Triangulation
    2.6 Assumptions

3 Executive Summary (Page No. - 26)

4 Premium Insights (Page No. - 30)
    4.1 PDX Models Market Overview
    4.2 Regional Analysis: Global Patient Derived Xenograft Models Market, By End User
    4.3 Global PDX Models Market, By Tumor Type, 2017 & 2022
    4.4 Regional Snapshot of the Global Patient Derived Xenograft Models Market

5 Market Overview (Page No. - 34)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Growing Demand for Personalized Medicine
                    5.2.1.2 Continuous Support for Cancer Research From Public as Well as Private Sector
                    5.2.1.3 Growth in the Number of Pharmaceutical R&D Activities
           5.2.2 Restraints
                    5.2.2.1 High Cost of Personalized PDX Models
                    5.2.2.2 Stringent Guidelines for the Use of Animal Models in Cancer Research
           5.2.3 Opportunity
                    5.2.3.1 Rising Demand for Humanized PDX Models
           5.2.4 Challenge
                    5.2.4.1 Limitations of PDX Models

6 Patient Derived Xenograft Models Market, By Type (Page No. - 40)
    6.1 Introduction
    6.2 Mice Models
    6.3 Rat Models

7 Patient Derived Xenograft Models Market, By Tumor Type (Page No. - 44)
    7.1 Introduction
    7.2 Gastrointestinal Tumor Models
    7.3 Gynecological Tumor Models
    7.4 Respiratory Tumor Models
    7.5 Urological Tumor Models
    7.6 Hematological Tumor Models
    7.7 Other Tumor Models

8 Patient Derived Xenograft Models Market, By Application (Page No. - 52)
    8.1 Introduction
    8.2 Preclinical Drug Development and Basic Cancer Research
    8.3 Biomarker Analysis

9 Patient Derived Xenograft Models Market, By End User (Page No. - 56)
    9.1 Introduction
    9.2 Pharmaceutical & Biotechnology Companies
    9.3 Contract Research Organizations
    9.4 Academic & Research Institutions

10 Patient Derived Xenograft Models Market, By Region (Page No. - 62)
     10.1 Introduction
     10.2 North America
             10.2.1 US
                        10.2.1.1 Growing Focus on Cancer Research in the US
                        10.2.1.2 Rise in Mab Production
                        10.2.1.3 Development of Oncology Biosimilars Boosting the Demand for Preclinical Services
             10.2.2 Canada
                        10.2.2.1 Rising Stem Cell Research
     10.3 Europe
             10.3.1 Focus on Cancer Research and Treatment
             10.3.2 Germany: Growth of the Biotech Sector
             10.3.3 Spain: Availability of Venture Funding for Life Sciences
             10.3.4 Italy: Growth of the Biotech, Pharma Sectors
             10.3.5 Rising Research Investments in Sweden, Austria, and Denmark
     10.4 Asia Pacific
             10.4.1 Rising Focus on Precision Medicine and Personalized Medicine in China
             10.4.2 Strong Research Expenditure and Well-Structured Cros Industry in China
             10.4.3 Growing Focus of Pharmaceutical and Animal Research Model Suppliers on China
             10.4.4 Public and Private Investments in China’s Life Sciences Sector
             10.4.5 Initiatives to Reduce Long Approval Times in China
             10.4.6 Intellectual Property (Ip) Breaches, A Challenge for Market Growth in China
             10.4.7 Japan: Growth in Biomedical and Medical Research
             10.4.8 India: Rising R&D Expenditure
             10.4.9 Infrastructural Limitations in India
             10.4.10 Availability of Funding for Biomedical Research in Australia
             10.4.11 Rising Translational and Biomedical Research in SingAPOre
             10.4.12 Rising Pharmaceutical and Biotechnology R&D in Korea
     10.5 Rest of the World (RoW)
             10.5.1 Rising R&D in Brazil
             10.5.2 Growth of the Pharmaceutical and Biotechnology Industries in Saudi Arabia and the UAE

11 Competitive Landscape (Page No. - 89)
     11.1 Introduction
     11.2 Market Ranking Analysis
     11.3 Competitive Leadership Mapping
             11.3.1 Visionary Leaders
             11.3.2 Innovators
             11.3.3 Emerging Companies
             11.3.4 Dynamic Differentiators
     11.4 Competitive Benchmarking
             11.4.1 Strength of Product Portfolio
             11.4.2 Business Strategy Excellence

*Top 15 companies analyzed for this studies are - Crown Bioscience Inc. (US), Champions Oncology, Inc. (US), The Jackson Laboratory (US), Charles River Laboratories, International, Inc. (US), WuXi AppTec (China), ONCODESIGN (France), EPO Berlin-Buch GmbH   (Germany), Shanghai LIDE Biotech Co., Ltd. (China), Xentech (France), Horizon Discovery Group PLC (UK), Pharmatest Services Ltd. (Finland), Hera BioLabs (US), Urolead (France), Xenopat (Spain), Bioduro (US)

12 Company Profiles (Page No. - 94)
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
     12.1 Crown Bioscience Inc.
     12.2 the Jackson Laboratory
     12.3 Champions Oncology, Inc.
     12.4 Charles River Laboratories International, Inc.
     12.5 WuXi Apptec (Group of Subsidiaries Under WuXi Pharmatec)
     12.6 ONCODESIGN
     12.7 Horizon Discovery Group PLC  (Sage Labs, Inc.)
     12.8 Pharmatest Services Ltd.
     12.9 Hera Biolabs
     12.10 EPO Berlin-Buch GmbH
     12.11 Xentech
     12.12 Urolead

*Details on Marketsandmarkets View, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 140)
     13.1 Discussion Guide
     13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.3 Introducing RT: Real-Time Market Intelligence
     13.4 Available Customizations
     13.5 Related Reports
     13.6 Author Details

List of Tables (44 Tables)

Table 1 Global PDX Models Market, By Type, 2015–2022 (USD Million)
Table 2 PDX Mice Models Market, By Region, 2015–2022 (USD Million)
Table 3 PDX Rat Models Market, By Region, 2015–2022 (USD Thousand)
Table 4 Global Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 5 Gastrointestinal Tumor Models Market, By Region, 2015–2022 (USD Million)
Table 6 Gynecological Tumor Models Market, By Region, 2015–2022 (USD Million)
Table 7 Respiratory Tumor Models Market, By Region, 2015–2022 (USD Million)
Table 8 Urological Tumor Models Market, By Region, 2015–2022 (USD Thousand)
Table 9 Hematological Tumor Models Market, By Region, 2015–2022 (USD Thousand)
Table 10 Other Tumor Models Market, By Region, 2015–2022 (USD Million)
Table 11 Global PDX Models Market, By Application, 2015–2022 (USD Million)
Table 12 Patient Derived Xenograft Models Market for Preclinical Drug Development and Basic Cancer Research, By Region, 2015–2022 (USD Million)
Table 13 PDX Models Market for Biomarker Analysis, By Region, 2015–2022 (USD Million)
Table 14 Global Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 15 PDX Models Market for Pharmaceutical & Biotechnology Companies, By Region, 2015–2022 (USD Million)
Table 16 PDX Models Market for Contract Research Organizations,  By Region, 2015–2022 (USD Million)
Table 17 Patient Derived Xenograft Models Market for Academic & Research Institutions, By Region, 2015–2022 (USD Million)
Table 18 Global Market, By Region, 2015–2022 (USD Million)
Table 19 North America: PDX Models Market, By Country, 2015-2022 (USD Million)
Table 20 North America: Patient Derived Xenograft Models Market, By Type, 2015–2022 (USD Million)
Table 21 North America: Market, By Tumor Type, 2015–2022 (USD Million)
Table 22 North America: Market, By Application, 2015–2022 (USD Million)
Table 23 North America: Market, By End User, 2015–2022 (USD Million)
Table 24 US: PDX Models Market, By Type, 2015–2022 (USD Million)
Table 25 US: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 26 US: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 27 US: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 28 Canada: PDX Models Market, By Type, 2015–2022 (USD Million)
Table 29 Canada: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 30 Canada: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 31 Canada: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 32 Europe: PDX Models Market, By Type, 2015–2022 (USD Million)
Table 33 Europe: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 34 Europe: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 35 Europe: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 36 Japan: Significant Partnerships
Table 37 Asia Pacific: PDX Models Market, By Type, 2015–2022 (USD Million)
Table 38 Asia Pacific: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 39 Asia Pacific: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 40 Asia Pacific: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 41 RoW: PDX Models Market, By Type, 2015–2022 (USD Thousand)
Table 42 RoW: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Thousand)
Table 43 RoW: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 44 RoW: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
 
 
List of Figures (34 Figures)
 
 
Figure 1 Global PDX Models Market: Research Methodology Steps
Figure 2 Sampling Frame: Primary Research
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market Size Estimation Methodology: Bottom-Up Approach
Figure 5 Market Size Estimation Methodology: Top-Down Approach
Figure 6 Market Forecast Methodology
Figure 7 Data Triangulation Methodology
Figure 8 Global PDX Models Market, By Type (2017)
Figure 9 Global Patient Derived Xenograft Models Market, By Tumor Type (2017)
Figure 10 Global PDX Models Market, By Application
Figure 11 Global Patient Derived Xenograft Models Market, By End User
Figure 12 Asia Pacific to Witness Highest Growth During the Forecast Period
Figure 13 Growing Cancer Research to Drive the Global PDX Models Market
Figure 14 North America is Expected to Dominate the Patient Derived Xenograft Models Market in 2017
Figure 15 Gastrointestinal Tumors to Account for the Largest Share of the Market in 2017
Figure 16 The Asia Pacific Region to Grow at the Highest CAGR During the Forecast Period
Figure 17 PDX Models Market: Drivers, Restraints, Opportunities, and Challenges
Figure 18 Mice Models to Dominate the Patient Derived Xenograft Models Market During the Forecast Period
Figure 19 Gastrointestinal Tumor Models is Expected to Account for the Largest Market Share in 2017
Figure 20 Preclinical Drug Development and Basic Cancer Research Applications to Dominate the PDX Models Market
Figure 21 Contract Research Organizations to Register the Highest CAGR During the Forecast Period
Figure 22 Asia Pacific to Grow at the Highest CAGR in the Patient Derived Xenograft Models Market
Figure 23 North America: PDX Models Market Snapshot
Figure 24 Europe: Patient Derived Xenograft Models Market Snapshot
Figure 25 Asia Pacific: PDX Models Market Snapshot
Figure 26 RoW: Patient Derived Xenograft Models Market Snapshot
Figure 27 Global PDX Model Market Ranking (As of 2016)
Figure 28 PDX Models Market (Global) Competitive Leadership Mapping,2017
Figure 29 The Jackson Laboratory: Company Snapshot (2016)
Figure 30 Champions Oncology, Inc.: Company Snapshot (2016)
Figure 31 Charles River Laboratories International, Inc.: Company Snapshot (2016)
Figure 32 WuXi Pharmatec: Company Snapshot (2015)
Figure 33 ONCODESIGN: Company Snapshot (2016)
Figure 34 Horizon Discovery Group PLC: Company Snapshot (2016)